Concord, CA 的 肥胖症 臨床試驗
18 項針對 肥胖症 的研究正在 Concord（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
招募中2 期
- John Muir Health - Concord /ID# 282469, Concord
- Diablo Clinical Research /ID# 282530, Walnut Creek · 距離 5 英里
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
招募中3 期
- Diablo Clinical Research, Inc., Walnut Creek · 距離 5 英里
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
招募中2 期
- Diablo Clinical Research - Flourish Research, Walnut Creek · 距離 5 英里
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
招募中3 期
- Diablo Clinical Research, Inc., Walnut Creek · 距離 5 英里
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
招募中3 期
- Diablo Clinical Research, Inc., Walnut Creek · 距離 5 英里
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
招募中3 期
- Research Site, Walnut Creek · 距離 5 英里
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
招募中3 期
- Diablo Clinical Research, Inc., Walnut Creek · 距離 5 英里
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
招募中3 期
- Research Site, Walnut Creek · 距離 5 英里
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
招募中3 期
- Diablo Clinical Research, Walnut Creek · 距離 5 英里
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
招募中3 期
- Diablo Clinical Research, Inc., Walnut Creek · 距離 5 英里
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
招募中2 期
- Diablo Clinical Research, Inc., Walnut Creek · 距離 5 英里
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
招募中3 期
- Diablo Clinical Research, Inc., Walnut Creek · 距離 5 英里
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
招募中2 期
- Diablo Clinical Research, Inc., Walnut Creek · 距離 5 英里
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
招募中3 期
- Diablo Clinical Research, Walnut Creek · 距離 5 英里
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
招募中3 期
- John Muir Physicians Network, Concord
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
招募中2 期
- Diablo Clinical Research - Flourish Research, Walnut Creek · 距離 5 英里
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
招募中3 期
- Diablo Clinical Research, Inc., Walnut Creek · 距離 5 英里
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
招募中1 期
- Diablo Clinical Research, Inc., Walnut Creek · 距離 5 英里
其他城市的 肥胖症 試驗
- Houston, TX43 項研究
- Chicago, IL41 項研究
- New York City, NY40 項研究
- San Antonio, TX40 項研究
- Washington, DC33 項研究
- Orlando, FL31 項研究
- Dallas, TX30 項研究
- Boston, MA28 項研究
- Las Vegas, NV27 項研究
- Miami, FL27 項研究
- Baltimore, MD25 項研究
- Jacksonville, FL25 項研究
Concord 的其他研究
- 過重16 項研究
- 非小細胞肺癌14 項研究
- 重度憂鬱症12 項研究
- 第二型糖尿病10 項研究
- 肺癌9 項研究
- 乳癌9 項研究
- 偏頭痛8 項研究
- 癌症（所有類型）7 項研究
- 前列腺癌6 項研究
- 憂鬱症6 項研究
- 高血壓5 項研究
- 糖尿病5 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。